31 filings
8-K
SQZB
SQZ Biotechnologies Co
22 Dec 23
Entry into a Material Definitive Agreement
5:18pm
8-K
SQZB
SQZ Biotechnologies Co
2 Oct 23
Cost Associated with Exit or Disposal Activities
5:17pm
8-K
SQZB
SQZ Biotechnologies Co
15 Sep 23
Termination of a Material Definitive Agreement
9:04am
8-K
SQZB
SQZ Biotechnologies Co
25 Jul 23
Other Events
7:34am
8-K
SQZB
SQZ Biotechnologies Co
7 Jul 23
Departure of Directors or Certain Officers
4:30pm
8-K
5zkus
3 Jul 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
1:53pm
8-K
svz m75l02e
15 Jun 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:37pm
8-K
6cg5b5r4
10 Apr 23
Departure of Directors or Certain Officers
4:30pm
8-K
cknnpg x8r9339ro1
18 Jan 23
SQZ Biotechnologies Receives Notice Regarding Continued Listing Standards From the New York Stock Exchange
4:36pm
8-K
pp4dhwynakylz
6 Dec 22
Designation Represents Potential to Bring Important New Therapy to Patients Earlier
4:23pm
8-K
6wv7h
30 Nov 22
Cost Associated with Exit or Disposal Activities
4:32pm
8-K
wmc7kjb9lri
6 Sep 22
SQZ Biotechnologies Announces Leadership Transition
4:33pm
8-K
ct5a07s8
11 Jul 22
SQZ Biotechnologies Appoints Micah Zajic as Chief Financial Officer
4:49pm
8-K
0rdii
16 Jun 22
Submission of Matters to a Vote of Security Holders
8:19am
8-K
kw4qfhh1jr3 to
31 May 22
Experienced Drug Developer Brings Over 25 Years of Clinical Development Industry Knowledge Across Oncology, Immunology, and Infectious Disease
4:52pm
8-K
pal90987kiddozse
19 May 22
Regulation FD Disclosure
4:05pm
8-K
28gnug1 ovrcwxxj
24 Jan 22
SQZ Biotechnologies Announces FDA Clearance of Investigational New Drug (IND) Application for SQZ-eAPC-HPV, a Novel mRNA-based Cell Therapy for the Treatment of HPV16 Positive Solid Tumors
7:01am
8-K
67uhn 43l12v6fuvck
9 Dec 21
Other Events
7:30am
8-K
z19 4b8ohz58jemr
2 Dec 21
Other Events
6:28am
8-K/A
6ay6 l2t5p
18 Nov 21
Departure of Directors or Certain Officers
5:03pm